Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M

Vanda Pharmaceuticals Inc.

2024-FY EPS reported -$0.33 revenue$198,772,000

Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).
Full year 2024 revenue $198.8M (+3%); net loss $18.9M vs net income $2.5M in 2023.
2025 revenue guidance $210-250M; targets psychiatry portfolio >$750M by 2030.
Bysanti NDA for bipolar/schizophrenia expected Q1 2025; Tradipitant NDA for motion sickness submitted Q4 2024.
Imsidolimab BLA for generalized pustular psoriasis expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.